Clinical trial · Observational
Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to determine the relationship between Lymphedema and Myofascial Pain Syndrome in Breast Cancer Patients. The main questions it aims to answer: * Is there a relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients? * Does the existence of lymphedema in breast cancer patients affect the distribution and the pain threshold values of trigger points seen in Myofascial Pain Syndrome? * What is the impact of Myofascial pain syndrome seen in breast cancer associted lymhedema patients on upper extremity function and quality of life?
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer Female | — | UNRESOLVED | — |
| Lymphedema | — | UNRESOLVED | — |
| Lymphedema of Upper Limb | — | UNRESOLVED | — |
| Myofascial Pain Syndrome | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic Criteria of Myofascial Pain Syndrome | Diagnostic Test | — | UNRESOLVED |
| Hand Grip Test | Diagnostic Test | — | UNRESOLVED |
| Lymqol-Arm | Diagnostic Test | — | UNRESOLVED |
| Quick DASH | Diagnostic Test | — | UNRESOLVED |
| Range of Motion of Shoulde Joint | Diagnostic Test | — | UNRESOLVED |
| The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer | Diagnostic Test | — | UNRESOLVED |
| VAS | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group 1 (Patients with Stage 0 lymphedema)
- description
- It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent). The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55)
- interventionNames
- Diagnostic Test: Diagnostic Criteria of Myofascial Pain Syndrome
- Diagnostic Test: The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer
- Diagnostic Test: Hand Grip Test
- Diagnostic Test: VAS
- Diagnostic Test: Quick DASH
- Diagnostic Test: Lymqol-Arm
- Diagnostic Test: Range of Motion of Shoulde Joint
- label
- Group 2 (Patients with Stage 1,2 or 3 lymphedema)
- description
- Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55)
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria : * Breast cancer patients aged between 18-75 who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy providing a written consent to participate in the study Exclusion Criteria : * Patients who do not agree to participate the study * Patients who had signs of active infection as lymphangitis, cellulitis, fungus * Bilateral breast cancer patients * Uncontrolled Psychiatric illness
References
Publications (0)
Data not yet available